Melinta Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2000-01-01
- Employees
- 290
- Market Cap
- -
- Website
- http://melinta.com
Clinical Trials
50
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (44 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
- Conditions
- Acute PyelonephritisComplicated Urinary Tract Infection
- Interventions
- Drug: Meropenem-VaborbactamDrug: Antibiotics
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-07-29
- Target Recruit Count
- 66
- Registration Number
- NCT06672978
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇧🇬Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski - 2003" OOD, Department of Pediatric Diseases, Dupnitsa, Bulgaria
🇧🇬Multiprofile Hospital for Active Treatment - Pazardzhik, Second Department of Pediatric Diseases, Pazardzhik, Bulgaria
A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy Adults
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06612255
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom
Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients
- Conditions
- Acute Bacterial Skin and Skin Structure Infection
- Interventions
- Drug: Current Formulation of Oritavancin
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT03873987
- Locations
- 🇺🇸
ML-ORI-102 Study Site, Somers Point, New Jersey, United States
Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03534622
- Locations
- 🇺🇸
Pulmonary Associates, Phoenix, Arizona, United States
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 325
- Registration Number
- NCT03159403
- Locations
- 🇺🇸
Birmingham Infectious Disease and Infusion, Birmingham, Alabama, United States
🇺🇸Santa Barbara Cottage Hospital, Santa Barbara, California, United States
🇺🇸Florida Infectious Disease Care, Fort Myers, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next